AbbVie (ABBV) Other Gross PP&E Adjustments (2012 - 2025)
AbbVie (ABBV) reported Other Gross PP&E Adjustments of $13.5 billion for Q4 2025, up 16.82% year-over-year from $11.5 billion in Q4 2024, and up 16.82% on a QoQ basis from $11.5 billion in Q4 2024.
AbbVie (ABBV) has 14 years of Other Gross PP&E Adjustments data on file, last reported at $13.5 billion in Q4 2025.
- Quarterly Other Gross PP&E Adjustments rose 16.82% year-over-year to $13.5 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.5 billion (up 16.82% YoY) and the FY2025 annual result came in at $13.5 billion, up 16.82% from the prior year.
- Other Gross PP&E Adjustments improved to $13.5 billion in Q4 2025 per ABBV's latest filing, from $11.5 billion in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $13.5 billion in Q4 2025 and bottomed at $10.7 billion in Q4 2021.
- The 5-year median for Other Gross PP&E Adjustments is $11.5 billion (2024), against an average of $11.7 billion.
- The widest annual swing landed in 2021, when Other Gross PP&E Adjustments declined 1.27%; it then advanced 16.82% in 2025.
- Tracing ABBV's Other Gross PP&E Adjustments over 5 years: stood at $10.7 billion in 2021, then advanced by 2.5% to $11.0 billion in 2022, then gained by 5.83% to $11.6 billion in 2023, then dropped by 0.48% to $11.5 billion in 2024, then advanced by 16.82% to $13.5 billion in 2025.
- Per Business Quant, the three latest ABBV Other Gross PP&E Adjustments figures stand at $13.5 billion (Q4 2025), $11.5 billion (Q4 2024), and $11.6 billion (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 49.60 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | -2.70 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 8.42 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -1.53 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.49 Bn |
| Dec 31, 2025 | 13.49 Bn |
| Dec 31, 2024 | 11.54 Bn |
| Dec 31, 2024 | 11.54 Bn |
| Dec 31, 2023 | 11.60 Bn |
| Dec 31, 2023 | 11.60 Bn |
| Dec 31, 2022 | 10.96 Bn |
| Dec 31, 2022 | 10.96 Bn |
| Dec 31, 2021 | 10.69 Bn |
| Dec 31, 2021 | 10.69 Bn |
| Dec 31, 2020 | 10.83 Bn |
| Dec 31, 2020 | 10.83 Bn |
| Dec 31, 2019 | 7.84 Bn |
| Dec 31, 2019 | 7.84 Bn |
| Sep 30, 2019 | -357.00 Mn |
| Sep 30, 2019 | -357.00 Mn |
| Jun 30, 2019 | -27.00 Mn |
| Jun 30, 2019 | -27.00 Mn |
| Mar 31, 2019 | -405.00 Mn |
| Mar 31, 2019 | -405.00 Mn |
| Dec 31, 2018 | 8.29 Bn |
| Dec 31, 2018 | 8.29 Bn |
| Dec 31, 2017 | 7.95 Bn |
| Dec 31, 2017 | 7.95 Bn |
| Dec 31, 2016 | 7.41 Bn |
| Dec 31, 2016 | 7.41 Bn |
| Sep 30, 2016 | -800.00 Mn |
| Sep 30, 2016 | -800.00 Mn |
| Jun 30, 2016 | 6.89 Bn |
| Jun 30, 2016 | 6.89 Bn |
| Mar 31, 2016 | 6.78 Bn |
| Mar 31, 2016 | 6.78 Bn |
| Dec 31, 2015 | 7.33 Bn |
| Dec 31, 2015 | 7.33 Bn |
| Sep 30, 2015 | 6.89 Bn |
| Sep 30, 2015 | 6.89 Bn |
| Jun 30, 2015 | 7.17 Bn |
| Jun 30, 2015 | 7.17 Bn |
| Mar 31, 2015 | 6.99 Bn |
| Mar 31, 2015 | 6.99 Bn |
| Dec 31, 2014 | 7.11 Bn |
| Dec 31, 2014 | 7.11 Bn |
| Sep 30, 2014 | 7.06 Bn |
| Sep 30, 2014 | 7.06 Bn |
| Dec 31, 2013 | 6.91 Bn |
| Dec 31, 2013 | 6.91 Bn |
| Sep 30, 2013 | 6.79 Bn |
| Sep 30, 2013 | 6.79 Bn |
| Jun 30, 2013 | 6.65 Bn |
| Jun 30, 2013 | 6.65 Bn |
| Mar 31, 2013 | 6.55 Bn |
| Mar 31, 2013 | 6.55 Bn |
| Dec 31, 2012 | 6.54 Bn |
| Dec 31, 2012 | 6.54 Bn |